Value of p16(INK4a) in the diagnosis of low-grade urothelial carcinoma of the urinary bladder in urinary cytology. 2012

Francesc Alameda, and Nuria Juanpere, and Lara Pijuan, and Belen Lloveras, and Javier Gimeno, and Teresa Baró, and Marta Salido, and Sergio Serrano, and Josep Lloreta
Department of Pathology, Hospital of the Sea, Barcelona, Spain. 86780@hospitaldelmar.cat

BACKGROUND The sensitivity of urinary cytology for the diagnosis of urothelial carcinomas is low, particularly in low-grade carcinomas. The UroVysion test is a fluorescent in situ hybridization multiprobe assay that increases the sensitivity of urinary cytology. However, this test is not widely available. P16(INK4a) , a protein involved in cell cycle progression, is overexpressed in urothelial carcinoma. Immunocytochemical expression of p16(INK4a) has been examined in biopsy samples from urothelial carcinomas, but few studies have addressed this protein in urine cytology. METHODS The authors compared the results of p16(INK4a) immunoreactivity in cytology and biopsy samples from 83 cases, including low-grade urothelial carcinomas, reactive epithelial lesions, and negative cases. RESULTS p16(INK4a) assessment of in urine cytology samples showed a sensitivity of 66.7% and a specificity of 82.8% in the diagnosis of low-grade urothelial carcinomas. CONCLUSIONS On the basis of these results, the authors propose that immunocytochemical detection of p16(INK4a) is a reliable tool in urine cytology, both for the diagnosis of low-grade urothelial carcinomas and for follow-up purposes. More retrospective and prospective studies are required to verify these results.

UI MeSH Term Description Entries
D007124 Immunoenzyme Techniques Immunologic techniques based on the use of: (1) enzyme-antibody conjugates; (2) enzyme-antigen conjugates; (3) antienzyme antibody followed by its homologous enzyme; or (4) enzyme-antienzyme complexes. These are used histologically for visualizing or labeling tissue specimens. Antibody Enzyme Technique, Unlabeled,Enzyme Immunoassay,Enzyme-Labeled Antibody Technique,Immunoassay, Enzyme,Immunoperoxidase Techniques,Peroxidase-Antiperoxidase Complex Technique,Peroxidase-Labeled Antibody Technique,Antibody Enzyme Technic, Unlabeled,Enzyme-Labeled Antibody Technic,Immunoenzyme Technics,Immunoperoxidase Technics,Peroxidase-Antiperoxidase Complex Technic,Peroxidase-Labeled Antibody Technic,Antibody Technic, Enzyme-Labeled,Antibody Technic, Peroxidase-Labeled,Antibody Technics, Enzyme-Labeled,Antibody Technics, Peroxidase-Labeled,Antibody Technique, Enzyme-Labeled,Antibody Technique, Peroxidase-Labeled,Antibody Techniques, Enzyme-Labeled,Antibody Techniques, Peroxidase-Labeled,Enzyme Immunoassays,Enzyme Labeled Antibody Technic,Enzyme Labeled Antibody Technique,Enzyme-Labeled Antibody Technics,Enzyme-Labeled Antibody Techniques,Immunoassays, Enzyme,Immunoenzyme Technic,Immunoenzyme Technique,Immunoperoxidase Technic,Immunoperoxidase Technique,Peroxidase Antiperoxidase Complex Technic,Peroxidase Antiperoxidase Complex Technique,Peroxidase Labeled Antibody Technic,Peroxidase Labeled Antibody Technique,Peroxidase-Antiperoxidase Complex Technics,Peroxidase-Antiperoxidase Complex Techniques,Peroxidase-Labeled Antibody Technics,Peroxidase-Labeled Antibody Techniques,Technic, Enzyme-Labeled Antibody,Technic, Immunoenzyme,Technic, Immunoperoxidase,Technic, Peroxidase-Antiperoxidase Complex,Technic, Peroxidase-Labeled Antibody,Technics, Enzyme-Labeled Antibody,Technics, Immunoenzyme,Technics, Immunoperoxidase,Technics, Peroxidase-Antiperoxidase Complex,Technics, Peroxidase-Labeled Antibody,Technique, Enzyme-Labeled Antibody,Technique, Immunoenzyme,Technique, Immunoperoxidase,Technique, Peroxidase-Antiperoxidase Complex,Technique, Peroxidase-Labeled Antibody,Techniques, Enzyme-Labeled Antibody,Techniques, Immunoenzyme,Techniques, Immunoperoxidase,Techniques, Peroxidase-Antiperoxidase Complex,Techniques, Peroxidase-Labeled Antibody
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D001749 Urinary Bladder Neoplasms Tumors or cancer of the URINARY BLADDER. Bladder Cancer,Bladder Neoplasms,Cancer of Bladder,Bladder Tumors,Cancer of the Bladder,Malignant Tumor of Urinary Bladder,Neoplasms, Bladder,Urinary Bladder Cancer,Bladder Cancers,Bladder Neoplasm,Bladder Tumor,Cancer, Bladder,Cancer, Urinary Bladder,Neoplasm, Bladder,Neoplasm, Urinary Bladder,Tumor, Bladder,Tumors, Bladder,Urinary Bladder Neoplasm
D002295 Carcinoma, Transitional Cell A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS. Carcinomas, Transitional Cell,Cell Carcinoma, Transitional,Cell Carcinomas, Transitional,Transitional Cell Carcinoma,Transitional Cell Carcinomas
D003581 Cytodiagnosis Diagnosis of the type and, when feasible, the cause of a pathologic process by means of microscopic study of cells in an exudate or other form of body fluid. (Stedman, 26th ed) Cytodiagnoses
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Francesc Alameda, and Nuria Juanpere, and Lara Pijuan, and Belen Lloveras, and Javier Gimeno, and Teresa Baró, and Marta Salido, and Sergio Serrano, and Josep Lloreta
September 2006, Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica,
Francesc Alameda, and Nuria Juanpere, and Lara Pijuan, and Belen Lloveras, and Javier Gimeno, and Teresa Baró, and Marta Salido, and Sergio Serrano, and Josep Lloreta
March 2014, Cancer cytopathology,
Francesc Alameda, and Nuria Juanpere, and Lara Pijuan, and Belen Lloveras, and Javier Gimeno, and Teresa Baró, and Marta Salido, and Sergio Serrano, and Josep Lloreta
September 2009, Der Urologe. Ausg. A,
Francesc Alameda, and Nuria Juanpere, and Lara Pijuan, and Belen Lloveras, and Javier Gimeno, and Teresa Baró, and Marta Salido, and Sergio Serrano, and Josep Lloreta
August 2020, Zhonghua bing li xue za zhi = Chinese journal of pathology,
Francesc Alameda, and Nuria Juanpere, and Lara Pijuan, and Belen Lloveras, and Javier Gimeno, and Teresa Baró, and Marta Salido, and Sergio Serrano, and Josep Lloreta
January 2021, Journal of cytology,
Francesc Alameda, and Nuria Juanpere, and Lara Pijuan, and Belen Lloveras, and Javier Gimeno, and Teresa Baró, and Marta Salido, and Sergio Serrano, and Josep Lloreta
January 1995, Acta cytologica,
Francesc Alameda, and Nuria Juanpere, and Lara Pijuan, and Belen Lloveras, and Javier Gimeno, and Teresa Baró, and Marta Salido, and Sergio Serrano, and Josep Lloreta
April 2010, International journal of surgical pathology,
Francesc Alameda, and Nuria Juanpere, and Lara Pijuan, and Belen Lloveras, and Javier Gimeno, and Teresa Baró, and Marta Salido, and Sergio Serrano, and Josep Lloreta
December 2015, American journal of clinical pathology,
Francesc Alameda, and Nuria Juanpere, and Lara Pijuan, and Belen Lloveras, and Javier Gimeno, and Teresa Baró, and Marta Salido, and Sergio Serrano, and Josep Lloreta
January 1988, Minerva urologica e nefrologica = The Italian journal of urology and nephrology,
Francesc Alameda, and Nuria Juanpere, and Lara Pijuan, and Belen Lloveras, and Javier Gimeno, and Teresa Baró, and Marta Salido, and Sergio Serrano, and Josep Lloreta
December 2005, Urology,
Copied contents to your clipboard!